Objective High-grade Pap results (eg, atypical glandular cells [AGC], atypical squamous
cells cannot rule out HSIL [ASC-H], and high-grade squamous intraepithelial lesion [HSIL]) …

Objective Current US guidelines for cotesting recommend that the large numbers of women
who test Pap-negative, but human papillomavirus (HPV)–positive, return in 1 year, and …

Objective New screening guidelines recommend that human papillomavirus (HPV)–
negative/atypical squamous cells of undetermined significance (ASC-US) results be …

Objective In 2012, the US Preventive Services Task Force (USPSTF) and a consensus of 25
organizations endorsed concurrent cytology and human papillomavirus (HPV) testing …

Objective Low-grade squamous intraepithelial lesion (LSIL) Pap results do not typically lead
to human papillomavirus (HPV) testing. HPV triage is not cost-effective because most cases …

Objectives The next round of the American Society for Colposcopy and Cervical Pathology
(ASCCP)-sponsored cervical cancer screening and management guidelines will …

Objective Current US national guidelines recommend beginning screening at age 21 using
Pap tests only, with cotesting starting at age 30. To inform the management of Pap test …

Objective Most women referred for colposcopy are not diagnosed with cervical intraepithelial
neoplasia grade 2 or worse (CIN 2+) but, nonetheless, are typically asked to return much …

Purpose To describe the long-term (≥ 10 years) benefits of clinical human papillomavirus
(HPV) DNA testing for cervical precancer and cancer risk prediction. Methods …

Objective The US screening and management guidelines for cervical cancer are based on
the absolute risk of precancer estimated from large clinical cohorts and trials. Given the …